Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies
Michel Meignan, Anne‐Ségolène Cottereau, Annibale Versari, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 30, pp. 3618-3626
Closed Access | Times Cited: 278

Showing 1-25 of 278 citing articles:

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Laëtitia Vercellino, Roberta Di Blasi, Salim Kanoun, et al.
Blood Advances (2020) Vol. 4, Iss. 22, pp. 5607-5615
Open Access | Times Cited: 327
A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies
Fanny Orlhac, Jakoba J. Eertink, Anne‐Ségolène Cottereau, et al.
Journal of Nuclear Medicine (2021) Vol. 63, Iss. 2, pp. 172-179
Open Access | Times Cited: 184
A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy
Jiangdian Song, Jingyun Shi, Di Dong, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 15, pp. 3583-3592
Open Access | Times Cited: 176
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
Emmanuel Bachy, Matthew J. Maurer, Thomas M. Habermann, et al.
Blood (2018) Vol. 132, Iss. 1, pp. 49-58
Open Access | Times Cited: 175
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Anne‐Ségolène Cottereau, Annibale Versari, Annika Loft, et al.
Blood (2018) Vol. 131, Iss. 13, pp. 1456-1463
Open Access | Times Cited: 162
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
Carla Casulo, Jesse G. Dixon, Jennifer Le‐Rademacher, et al.
Blood (2022) Vol. 139, Iss. 11, pp. 1684-1693
Open Access | Times Cited: 113
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index
N. George Mikhaeel, Martijn W. Heymans, Jakoba J. Eertink, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 21, pp. 2352-2360
Open Access | Times Cited: 88
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)
Sattva S. Neelapu, Julio C. Chávez, Alison R. Sehgal, et al.
Blood (2023) Vol. 143, Iss. 6, pp. 496-506
Open Access | Times Cited: 55
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Martin Dreyling, Nathan Fowler, Michael Dickinson, et al.
Blood (2024) Vol. 143, Iss. 17, pp. 1713-1725
Open Access | Times Cited: 34
18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome
Anne‐Ségolène Cottereau, Christophe Nioche, Anne-Sophie Dirand, et al.
Journal of Nuclear Medicine (2019) Vol. 61, Iss. 1, pp. 40-45
Open Access | Times Cited: 132
Time to Prepare for Risk Adaptation in Lymphoma by Standardizing Measurement of Metabolic Tumor Burden
Sally F. Barrington, Michel Meignan
Journal of Nuclear Medicine (2019) Vol. 60, Iss. 8, pp. 1096-1102
Open Access | Times Cited: 129
Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma
Marie‐Hélène Delfau‐Larue, Axel Van Der Gucht, Jehan Dupuis, et al.
Blood Advances (2018) Vol. 2, Iss. 7, pp. 807-816
Open Access | Times Cited: 126
Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†
Anne‐Ségolène Cottereau, Michel Meignan, Christophe Nioche, et al.
Annals of Oncology (2020) Vol. 32, Iss. 3, pp. 404-411
Open Access | Times Cited: 120
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
Judith Trotman, Sally F. Barrington, David Belada, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 11, pp. 1530-1542
Open Access | Times Cited: 119
FDG‐PET/CT in the management of lymphomas: current status and future directions
Tarec Christoffer El‐Galaly, Diego Villa, Lars Christian Gormsen, et al.
Journal of Internal Medicine (2018) Vol. 284, Iss. 4, pp. 358-376
Open Access | Times Cited: 112
Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.
Paul Blanc‐Durand, Simon Jégou, Salim Kanoun, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2020) Vol. 48, Iss. 5, pp. 1362-1370
Closed Access | Times Cited: 104
Deep-Learning 18F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma
Nicolò Capobianco, Michel Meignan, Anne‐Ségolène Cottereau, et al.
Journal of Nuclear Medicine (2020) Vol. 62, Iss. 1, pp. 30-36
Open Access | Times Cited: 102
Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis
Baoping Guo, Xiaohong Tan, Qing Ke, et al.
PLoS ONE (2019) Vol. 14, Iss. 1, pp. e0210224-e0210224
Open Access | Times Cited: 97
Metabolic Tumor Volume Metrics in Lymphoma
Lale Kostakoğlu, Stéphane Chauvie
Seminars in Nuclear Medicine (2017) Vol. 48, Iss. 1, pp. 50-66
Closed Access | Times Cited: 94
Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial
Christine Hanoun, Andreas Hüttmann, Stefan Müller, et al.
European Journal of Cancer (2019) Vol. 124, pp. 25-36
Closed Access | Times Cited: 84
Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)
Nandita M. deSouza, Eric Achten, Ángel Alberich‐Bayarri, et al.
Insights into Imaging (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 80
Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium
Sally F. Barrington, Gerben J. C. Zwezerijnen, Henrica C. W. de Vet, et al.
Journal of Nuclear Medicine (2020) Vol. 62, Iss. 3, pp. 332-337
Open Access | Times Cited: 79
Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy
Nicolas Aide, Christophe Fruchart, Catherine Nganoa, et al.
European Radiology (2020) Vol. 30, Iss. 8, pp. 4623-4632
Closed Access | Times Cited: 74
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
Luc‐Matthieu Fornecker, Julien Lazarovici, Igor Aurer, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 2, pp. 327-335
Open Access | Times Cited: 43
PET/CT in Non-Hodgkin Lymphoma: An Update
Lucia Zanoni, Davide Bezzi, Cristina Nanni, et al.
Seminars in Nuclear Medicine (2022) Vol. 53, Iss. 3, pp. 320-351
Closed Access | Times Cited: 42
Page 1 - Next Page

Scroll to top